O Centro Africano de Prevenção e Luta contra Doenças (CDC-África) está preocupado com a divulgação de informações incorrectas através de meios de comunicação tradicionais e sociais sobre a prevenção e o tratamento de nova doença de coronavírus (COVID-19).
Março de 2020
O número de Estados Membros da União Africana a reportarem
casos do COVID-19 está a aumentar e existe uma probabilidade de transmissão comunitária. A OMS modificou recentemente a definição
de caso suspeito do COVID-19, de modo a incluir infecção respiratória aguda grave... e aconselha a testagem de todos os casos de doença respiratória aguda grave (SARI).1 Contudo, muitos Estados Membros ainda não começaram a implementar estas alterações, pois ainda estão a concentrar os esforços na vigilância de indivíduos com histórico de viagem para uma área com transmissão local do COVID-19. Isto significa que os doentes com sintomas semelhantes, mas sem contacto aparente, podem não ser investigados.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
COVID-19, recomendaciones para el manejo
farmacológico / COVID-19, recommendations for pharmacological management
SBMFC Recommendations for PHC during the Pandemic of COVID-19 (edition 4)
This document answers questions and gives recommendations so that the Brazilian PHC can quickly receive the best possible scientific synthesis on the current situation of the pandemic of COVID-19
Острая респираторная вирусная инфекция (ОРВИ) – острое
инфекционное заболевание респираторного тракта, проявляющееся
воспалением верхних дыхательных путей, в б...ольшинстве случаев
завершающееся спонтанным выздоровлением. ОРВИ, как правило, протекает с
катаральными симптомами (насморком, кашлем, болью в горле и др.),
признаками общей интоксикации, субфибрильной, реже фибрильной,
лихорадкой.
Основными возбудителями ОРВИ являются вирусы гриппа типа А и В,
респираторно-синцитиальный вирус (РСВ), вирусы парагриппа, риновирусы,
аденовирусы, человеческие метапневмовирусы, бокавирусы, сезонные
коронавирусы. Вирусы, способные вызывать тяжелые пневмонии, такие как
MERS-CoV и SARS-CoV-2 (возбудитель новой коронавирусной инфекции
COVID-19), могут клинически протекать как сезонные ОРВИ. Также
необходимо помнить, что ОРВИ могут иметь сочетанную этиологию, когда в
развитии инфекционного процесса участвует несколько возбудителей. (версия 2 16.04.2020)
medical treatment for acute respiratory viral infections in outpatient practice during the COVID-19 epidemic
more
Short Version
This clinical practice guideline was developed in order to provide recommendations for the management of critically ill adult patients with COVID-19 in intensive care units (ICUs).
v.1 (3 de abril de 2020)
Este guia de prática clínica fornece recomendações baseadas em evidências para o controle de infecção, coleta de amostras, cuidados de suporte, tratamento medicamentoso e prevenção de complicações. As recomendações são dirigidas a todos os profissionais de sa...de que atendem os pacientes no serviço de urgência/emergência e na unidade de terapia intensiva (UTI) (médicos com especialidade em medicina de urgência, pneumologia, medicina intensiva, clínica médica, anestesiologia, infectologia, fisioterapeutas respiratórios, enfermeiros e farmacêuticos). O guia deve ser usado por tomadores de decisão e membros de entidades governamentais relacionados com o tratamento de pacientes com COVID-19 em UTI na região das Américas. Este guia não incluirá aspectos relacionados com a nutrição, fisioterapia (exceto fisioterapia respiratória) e tratamento de complicações.
more
As information about COVID-19 is rapidly evolving, it can be challenging to navigate and synthesize all of the information. The purpose of this document is to provide a synthesized, indexed reference of accurate, standardized COVID-19 information from trustworthy sources. Information is presented in... simple, clear language to support the development of messages and materials needed for social and behavior change interventions.
more
Community feedback considered in this report was collected through information received from Community Engagement and Accountability (CEA) focal points,as well as through primary data collection,in 10 African countries.Red Cross and Red Crescent National Society CEA focal points were asked to share ...the main rumours, observation, beliefs, questions or suggestions they are hearing in their countries andto grade them according to their frequency. Focal points from the following countries provided information this way: Botswana, Burundi, Cameroon, Niger, South Africa.
more
Les retours d’information de la communauté présentés dans le présent rapport ont été recueillis par le biais des personnes chargées de l’engagement communautaire et de la redevabilité (CEA) dans 10pays africains, et grâce à la collecte de données primaires.Il a été demandé aux pers...onnes chargées du CEA de la Société nationale de la Croix-Rouge et du Croissant-Rouge de partager les principales rumeurs, observations, croyances, questions ou suggestions qu’ils entendent dans leur pays et de les classer par ordre de fréquence. Les chargés de mission du CEA ont fourni des informations de cette manière aux pays suivants: Afrique du Sud, Botswana, Burundi, Cameroun, Niger.
more
Supply of essential medicines and health technologies (6 April 2020)
This paper is one of a set of technical guidance papers developed by the WHO Regional Office for Europe to provide practical information and resources for decision-makers on measures to strengthen the health system response to C...OVID-19.
The purpose of this paper is to provide WHO Regional Office for Europe Country Offices and Member States with guidance on how to maintain supplies of medicines and health technologies, including devices, diagnostics and blood products, during the COVID-19 outbreak.
more
9 April 2020
WHO has published the guidance “Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected” This document is intended for clinicians taking care of hospitalized adult and paediatric patients with severe acute respiratory infection (SARI) whe...n COVID-19 infection is suspected. Optimized supportive care should be provided to ensure the best possible chance for survival of COVID-19 patients as described in the WHO guidance:
1. Management of severe COVID-19 requires oxygen therapy and monitoring. Supplemental oxygen therapy should be given immediately to patients with SARI and respiratory distress, hypoxaemia or shock.
2. Management of critical COVID-19 (acute respiratory distress syndrome (ARDS)) requires advanced oxygen/ventilatory support.
more
On 31st December 2019, the World Health Organization (WHO) China Country Office was informed of cases of pneumonia of unknown etiology (unknown cause) detected in Wuhan City, Hubei Province of China. On 7th January 2020, Chinese authorities identified a new strain of Coronavirus as the causative age...nt for the disease. The virus has been renamed by WHO as SARS-CoV-2 and the disease caused by it as COVID-19. The disease since its first detection in China has now spread to over 200 countries/territories, with reports of local transmission happening in more than 160 of these countries/territories. As per WHO (as of 1st April, 2020), there has been a total of 823626 confirmed cases and 40598 deaths due to COVID-19 worldwide.
In India, as on 2nd April, 2020, 1965 confirmed cases (including 51 foreign nationals) and 50 deaths reported from 29 States/UTs. Large number of cases has been reported from Delhi, Karnataka, Kerala, Maharashtra, Rajasthan, Tamil Nadu, Telangana and Uttar Pradesh.
more
Accessed on 03.03.2020
Cet article documente le processus de mise en œuvre du Traitement préventif intermittent TPI), une stratégie de prévention du paludisme dont l’administration est couplée au Programme élargi de vaccination (PEV) dans les services de santé, les réactions des prestat...aires, des populations et leurs facteurs explicatifs. Les résultats montrent que l’absence de connaissances adéquates à propos du TPI n’a pas empêché son appropriation par les communautés, dans la mesure où les perceptions lui accordent une valeur pratique et l’intègrent dans les besoins ressentis. C’est pourquoi les enfants ont reçu, dans la grande majorité, les médicaments administrés. Certains comportements en décalage s’expliquent plus par des contraintes, des insuffisances du système de santé et de vaccination que par un refus. Chez les prestataires de soins, l’information a été plus disponible du côté les infirmiers étatiques. Cependant, les processus de détournement et les attitudes d’indifférence étaient plus visibles chez ces derniers.
more
Antimalarial drug resistance has emerged as a threat to global malaria control efforts, particularly in the Greater Mekong subregion. Drawing on data collected through more than 1000 therapeutic efficacy studies as well as molecular marker studies of Plasmodium falciparum drug resistance, the Report... on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019) presents a decade’s worth of data on drug efficacy and surveillance, as well as recommendations to monitor and protect the efficacy of malaria treatment in the decades to come.
more
The 2020 edition of the World malaria report takes a historical look at key milestones that helped shape the global response to the disease over the last 2 decades – a period of unprecedented success in malaria control. The report features a detailed analysis on progress towards the 2020 milestone...s of WHO’s global malaria strategy and a special section on malaria and the COVID-19 pandemic.
As in past years, the report provides an up-to-date assessment of the burden of malaria at global, regional and country levels. It tracks investments in malaria programmes and research as well as progress across all intervention areas. This latest report draws on data from 87 countries and territories with ongoing malaria transmission.
more
ESTA NOTA INFORMATIVA SUBSTITUI A NOTA INFORMATIVA Nº 11/2020-SE/GAB/SE/MS, DE 15 DE JUNHO DE 2020, QUE SUBSTITUIU A NOTA INFORMATIVANº 9/2020-SE/GAB/SE/MS, DE 20 DE MAIO DE 2020